What is AbbVie Inc.'s earnings per share (EPS)?

AbbVie Inc. (ABBV) reported diluted earnings per share of $2.36 for fiscal year 2025. This represents a -1.3% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

AbbVie Inc. (ABBV) Financials

ABBV

Trailing 12 months to June 30, 2026

Revenue $64.4B +10.4% YoY

Net Income $6.3B +67.7% YoY

EPS (Diluted) $3.54 +68.6% YoY

Free Cash Flow $18.2B -0.2% YoY

Market Cap $464.4B as of Oct 5, 2026

Price / Sales 7.2x on $64.4B revenue, trailing 12 months to June 30, 2026

Price / Earnings 73.6x on $6.3B net income, trailing 12 months to June 30, 2026

Price / Book n/m negative shareholder equity, so no book multiple, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 5, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 3, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 3, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the ABBV SEC filings page.

AbbVie Inc. (ABBV) reported $64.4B in revenue over the twelve months to Jun 30, 2026, up 10.4% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI ABBV FY2025 2026-10-04

AbbVie’s 2025 recovery restored sales and operating margin, but cash generation now coexists with a balance sheet carrying negative equity.

FY2025 operating cash flow of $19.0B was more than four times net income of $4.2B, showing that reported earnings substantially understate cash produced by the business. Free cash flow still reached $17.8B, so the earnings decline has not translated proportionally into cash generation.

Sales reached $61.2B in FY2025, reversing the prior year’s lower base. Operating margin recovered to 24.7% from 16.2% while gross margin stayed near 70.2%, indicating that the improvement occurred mainly below gross profit rather than through a major change in production economics.

Liabilities exceeded assets by roughly $3.3B in FY2025, leaving reported equity at -$3.3B. A current ratio of 0.7% indicates current obligations exceed current assets, making ongoing cash generation an important part of the company’s financing structure.

Financial Health Signals

Financial Health Score 58/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of AbbVie Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

AbbVie Inc. has an operating margin of 24.6%, meaning the company retains $25 of operating profit per $100 of revenue. This strong profitability earns a score of 84/100, reflecting efficient cost management and pricing power. This is up from 16.2% the prior year.

Growth

AbbVie Inc.'s revenue grew 8.6% year-over-year to $61.2B, a solid pace of expansion. This earns a growth score of 54/100.

Leverage

Liquidity

AbbVie Inc.'s current ratio of 0.67 is below the typical benchmark, resulting in a score of 8/100. This tight liquidity could limit financial flexibility if cash inflows slow.

Cash Flow

AbbVie Inc. converts 29.1% of revenue into free cash flow ($17.8B). This strong cash generation earns a score of 95/100.

Returns

Altman Z-Score Grey Zone

2.57

AbbVie Inc. scores 2.57, placing it in the grey zone between 1.81 and 2.99. The score is driven primarily by a large market capitalization ($464.4B) relative to total liabilities ($137.2B). This signals moderate financial risk that warrants monitoring.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Strong

7/9

AbbVie Inc. passes 7 of 9 financial strength tests. 3 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Cash-Backed

4.50x

For every $1 of reported earnings, AbbVie Inc. generates $4.50 in operating cash flow ($19.0B OCF vs $4.2B net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Interest Coverage Safe

5.21x

AbbVie Inc. earns $5.21 in operating income for every $1 of interest expense ($15.1B vs $2.9B). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$17.0B

YoY+10.2%

QoQ+13.3%

5Y CAGR+4.0%

10Y CAGR+10.2%

AbbVie Inc. generated $17.0B in revenue in Q2 2026. This represents an increase of 10.2% from the same quarter a year earlier. Against the prior quarter it is up 13.3%.

EBITDA

$8.3B

YoY+19.3%

QoQ+40.5%

AbbVie Inc.'s EBITDA was $8.3B in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 19.3% from the same quarter a year earlier. Against the prior quarter it is up 40.5%.

Net Income

$3.6B

YoY+285.2%

QoQ+419.9%

5Y CAGR+36.4%

10Y CAGR+8.4%

AbbVie Inc. reported $3.6B in net income in Q2 2026. This represents an increase of 285.2% from the same quarter a year earlier. Against the prior quarter it is up 419.9%.

EPS (Diluted)

$2.03

YoY+290.4%

QoQ+420.5%

5Y CAGR+37.0%

10Y CAGR+7.6%

AbbVie Inc. earned $2.03 per diluted share (EPS) in Q2 2026. This represents an increase of 290.4% from the same quarter a year earlier. Against the prior quarter it is up 420.5%.

Cash & Balance Sheet

Free Cash Flow

$3.1B

YoY-36.2%

QoQ-12.6%

5Y CAGR-7.9%

10Y CAGR+5.7%

AbbVie Inc. generated $3.1B in free cash flow in Q2 2026, representing cash available after capex. This represents a decrease of 36.2% from the same quarter a year earlier. Against the prior quarter it is down 12.6%.

Cash & Debt

$6.6B

YoY+1.6%

QoQ-30.1%

5Y CAGR-5.1%

10Y CAGR+0.4%

AbbVie Inc. held $6.6B in cash against $62.5B in long-term debt as of Q2 2026.

Dividends Per Share

$1.73

YoY+5.5%

QoQ0.0%

AbbVie Inc. paid $1.73 per share in dividends in Q2 2026. This represents an increase of 5.5% from the same quarter a year earlier. It is unchanged from the prior quarter.

Shares Outstanding

1.77B

YoY0.0%

QoQ0.0%

5Y CAGR0.0%

10Y CAGR+0.8%

AbbVie Inc. had 1.77B shares outstanding in Q2 2026. That is unchanged from the same quarter a year earlier. It is unchanged from the prior quarter.

Margins & Returns

Gross Margin

74.7%

YoY+2.9pp

QoQ+2.9pp

5Y change+7.1pp

10Y change-3.5pp

AbbVie Inc.'s gross margin was 74.7% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is up 2.9 percentage points from the same quarter a year earlier. Against the prior quarter it is up 2.9 percentage points.

Operating Margin

37.9%

YoY+6.1pp

QoQ+11.3pp

AbbVie Inc.'s operating margin was 37.9% in Q2 2026, reflecting core business profitability. This is up 6.1 percentage points from the same quarter a year earlier. Against the prior quarter it is up 11.3 percentage points.

Net Margin

21.3%

YoY+15.2pp

QoQ+16.6pp

5Y change+15.8pp

10Y change-3.7pp

AbbVie Inc.'s net profit margin was 21.3% in Q2 2026, showing the share of revenue converted to profit. This is up 15.2 percentage points from the same quarter a year earlier. Against the prior quarter it is up 16.6 percentage points.

Return on Equity

Not reported for Q2 2026.

Capital Allocation

R&D Spending

$2.3B

YoY+10.0%

QoQ-5.2%

AbbVie Inc. invested $2.3B in research and development in Q2 2026. This represents an increase of 10.0% from the same quarter a year earlier. Against the prior quarter it is down 5.2%.

Share Buybacks

$9.0M

YoY-25.0%

QoQ-99.4%

5Y CAGR-2.1%

10Y CAGR-45.4%

AbbVie Inc. spent $9.0M on share buybacks in Q2 2026, returning capital to shareholders by reducing shares outstanding. This represents a decrease of 25.0% from the same quarter a year earlier. Against the prior quarter it is down 99.4%.

Capital Expenditures

$322.0M

YoY+19.7%

QoQ+21.5%

5Y CAGR+10.6%

10Y CAGR+9.4%

AbbVie Inc. invested $322.0M in capex in Q2 2026, funding long-term assets and infrastructure. This represents an increase of 19.7% from the same quarter a year earlier. Against the prior quarter it is up 21.5%.

ABBV Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ABBV quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	$64.4B	$61.2B+8.6%	$56.3B+3.7%	$54.3B-6.4%	$58.1B+3.3%	$56.2B+22.7%	$45.8B+37.7%	$33.3B+1.6%	$32.8B+16.1%	$28.2B+10.1%	$25.6B+12.2%	$22.9B+14.5%	$20.0B+6.2%	$18.8B+2.2%	$18.4B+5.4%	$17.4B
Cost of Revenue	N/A	$18.2B+7.7%	$16.9B-17.2%	$20.4B+17.2%	$17.4B-0.2%	$17.4B+13.4%	$15.4B+106.8%	$7.4B-3.6%	$7.7B+9.6%	$7.0B+20.7%	$5.8B+29.6%	$4.5B+1.7%	$4.4B-3.4%	$4.6B+1.6%	$4.5B-2.8%	$4.6B
Gross Profit	$46.0B	$43.0B+8.9%	$39.4B+16.3%	$33.9B-16.6%	$40.6B+4.9%	$38.8B+27.4%	$30.4B+17.8%	$25.8B+3.2%	$25.0B+18.2%	$21.2B+6.9%	$19.8B+7.9%	$18.4B+18.2%	$15.5B+9.3%	$14.2B+2.4%	$13.9B+8.3%	$12.8B
R&D Expenses	N/A	$9.1B-28.9%	$12.8B+66.7%	$7.7B+17.9%	$6.5B-6.0%	$6.9B+8.5%	$6.4B-0.4%	$6.4B-38.0%	$10.3B+106.3%	$5.0B+14.2%	$4.4B+2.3%	$4.3B+30.0%	$3.3B+15.5%	$2.9B+2.8%	$2.8B+6.1%	$2.6B
SG&A Expenses	N/A	$14.0B-5.0%	$14.8B+14.6%	$12.9B-15.6%	$15.3B+23.6%	$12.3B+9.3%	$11.3B+62.8%	$6.9B-6.2%	$7.4B+17.5%	$6.3B+7.0%	$5.9B-7.9%	$6.4B-17.3%	$7.7B+44.3%	$5.4B+7.3%	$5.0B-15.4%	$5.9B
Operating Income	N/A	$15.1B+65.0%	$9.1B-28.4%	$12.8B-29.6%	$18.1B+1.1%	$17.9B+57.7%	$11.4B-12.5%	$13.0B+103.4%	$6.4B-33.1%	$9.5B+2.2%	$9.3B+23.9%	$7.5B+121.0%	$3.4B-39.8%	$5.7B-2.6%	$5.8B+60.7%	$3.6B
EBITDA	N/A	$23.2B+32.5%	$17.5B-18.3%	$21.5B-19.3%	$26.6B+0.5%	$26.4B+48.3%	$17.8B+18.9%	$15.0B+84.1%	$8.1B-26.2%	$11.0B+4.9%	$10.5B+25.7%	$8.4B+99.5%	$4.2B-36.0%	$6.6B-5.8%	$7.0B+42.4%	$4.9B
Interest Expense	N/A	$2.9B+3.0%	$2.8B+26.3%	$2.2B-0.3%	$2.2B-8.0%	$2.4B-1.3%	$2.5B+37.6%	$1.8B+32.3%	$1.3B+17.2%	$1.1B+9.8%	$1.0B+45.6%	$719.0M+67.6%	$429.0M+43.5%	$299.0M+187.5%	$104.0M	N/A
Income Tax	N/A	$2.4B+514.7%	-$570.0M-141.4%	$1.4B-15.6%	$1.6B+13.3%	$1.4B+217.6%	-$1.2B-325.0%	$544.0M+211.0%	-$490.0M-120.3%	$2.4B+25.2%	$1.9B+28.6%	$1.5B+152.3%	$595.0M-50.6%	$1.2B+167.6%	$450.0M+91.5%	$235.0M
Net Income	$6.3B	$4.2B-1.2%	$4.3B-12.0%	$4.9B-58.9%	$11.8B+2.5%	$11.5B+150.0%	$4.6B-41.4%	$7.9B+38.6%	$5.7B+7.1%	$5.3B-10.8%	$6.0B+15.7%	$5.1B+190.0%	$1.8B-57.0%	$4.1B-21.7%	$5.3B+53.7%	$3.4B
EPS (Basic)	N/A	$2.37-1.2%	$2.40-12.1%	$2.73-58.9%	$6.65+2.6%	$6.48+137.4%	$2.73-48.5%	$5.30+44.4%	$3.67+10.9%	$3.31-9.3%	$3.65+15.9%	$3.15+183.8%	$1.11-57.0%	$2.58-23.0%	$3.35+53.7%	$2.18
EPS (Diluted)	$3.54	$2.36-1.3%	$2.39-12.1%	$2.72-59.0%	$6.63+2.8%	$6.45+137.1%	$2.72-48.5%	$5.28+44.3%	$3.66+10.9%	$3.30-9.1%	$3.63+16.0%	$3.13+184.5%	$1.10-57.0%	$2.56-23.6%	$3.35+53.7%	$2.18
Diluted Shares (Avg)	N/A	1.77B0.0%	1.77B0.0%	1.77B-0.3%	1.78B+0.1%	1.78B+6.2%	1.67B+12.7%	1.48B-4.0%	1.55B-3.6%	1.60B-1.7%	1.63B-0.4%	1.64B+1.7%	1.61B+0.4%	1.60B+1.7%	1.58B0.0%	1.58B

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$17.0B+10.2%	$15.0B+12.4%	$16.6B+10.0%	$15.8B+9.1%	$15.4B+6.6%	$13.3B+8.4%	$15.1B+5.6%	$14.5B+3.8%
Cost of Revenue	$4.3B-1.3%	$4.2B+5.4%	N/A	$5.3B+25.9%	$4.3B+3.4%	$4.0B-2.2%	N/A	$4.2B-35.1%
Gross Profit	$12.7B+14.6%	$10.8B+15.4%	$12.1B+12.7%	$10.5B+2.2%	$11.1B+8.0%	$9.3B+13.7%	$10.7B+24.5%	$10.2B+37.7%
R&D Expenses	$2.3B+10.0%	$2.5B+19.6%	N/A	$2.3B+8.9%	$2.1B+9.4%	$2.1B+6.6%	N/A	$2.1B+23.6%
SG&A Expenses	$3.6B+11.7%	$3.6B+8.7%	N/A	$3.6B-15.1%	$3.3B-3.7%	$3.3B-0.7%	N/A	$4.2B+24.7%
Operating Income	$6.4B+31.4%	$4.0B+6.9%	N/A	$1.9B-50.3%	$4.9B+22.4%	$3.7B+33.4%	N/A	$3.8B+68.0%
EBITDA	$8.3B+19.3%	$5.9B+2.7%	N/A	$4.0B-32.5%	$7.0B+14.8%	$5.8B+18.5%	N/A	$5.9B+32.3%
Interest Expense	$746.0M+0.8%	$717.0M+2.4%	N/A	$739.0M+2.6%	$740.0M+1.9%	$700.0M+6.1%	N/A	$720.0M+29.7%
Income Tax	$662.0M+8.0%	$342.0M-8.1%	N/A	$526.0M+1.2%	$613.0M-20.7%	$372.0M-2.9%	N/A	$520.0M+202.3%
Net Income	$3.6B+285.2%	$695.0M-46.0%	$1.8B+8354.5%	$186.0M-88.1%	$938.0M-31.5%	$1.3B-6.1%	-$22.0M-102.7%	$1.6B-12.2%
EPS (Basic)	$2.04+292.3%	$0.39-45.8%	$1.02+5200.0%	$0.10-88.6%	$0.52-32.5%	$0.72-6.5%	-$0.02-104.3%	$0.88-12.0%
EPS (Diluted)	$2.03+290.4%	$0.39-45.8%	$1.02	$0.10-88.6%	$0.52-32.5%	$0.72-6.5%	-$0.02	$0.88-12.0%
Diluted Shares (Avg)	1.77B0.0%	1.77B+0.1%	N/A	1.77B0.0%	1.77B0.0%	1.77B-0.1%	N/A	1.77B+0.1%

ABBV Balance Sheet

ABBV quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$134.0B-0.9%	$135.2B+0.3%	$134.7B-2.9%	$138.8B-5.3%	$146.5B-2.7%	$150.6B+69.0%	$89.1B+50.1%	$59.4B-16.2%	$70.8B+7.1%	$66.1B+24.6%	$53.0B+92.8%	$27.5B-5.8%	$29.2B+8.1%	$27.0B	N/A
Current Assets	$29.1B+13.6%	$25.6B-22.5%	$33.0B+15.9%	$28.5B+1.9%	$27.9B+15.5%	$24.2B-51.2%	$49.5B+192.2%	$16.9B-20.2%	$21.2B+31.1%	$16.2B-0.8%	$16.3B+1.4%	$16.1B-9.9%	$17.8B+16.2%	$15.4B	N/A
Cash & Equivalents	$5.2B-5.3%	$5.5B-56.9%	$12.8B+39.3%	$9.2B-5.6%	$9.7B+15.4%	$8.4B-78.8%	$39.9B+447.7%	$7.3B-21.6%	$9.3B+82.4%	$5.1B-39.3%	$8.4B+0.6%	$8.3B-13.0%	$9.6B+62.6%	$5.9B+21755.6%	$27.0M
Short-Term Investments	$28.0M-9.7%	$31.0M+1450.0%	$2.0M-92.9%	$28.0M-66.7%	$84.0M+180.0%	$30.0M	$0-100.0%	$772.0M+58.8%	$486.0M-63.3%	$1.3B+16437.5%	$8.0M-69.2%	$26.0M-91.3%	$300.0M-85.5%	$2.1B	$0
Inventory	$5.0B+18.4%	$4.2B+2.0%	$4.1B+14.5%	$3.6B+14.4%	$3.1B-5.5%	$3.3B+82.6%	$1.8B+13.0%	$1.6B0.0%	$1.6B+11.1%	$1.4B-16.0%	$1.7B+52.9%	$1.1B-2.3%	$1.1B+5.4%	$1.1B	N/A
Accounts Receivable	$12.6B+15.3%	$10.9B-2.1%	$11.2B-0.9%	$11.3B+12.8%	$10.0B+13.1%	$8.8B+62.5%	$5.4B+0.8%	$5.4B+5.8%	$5.1B+6.9%	$4.8B+0.6%	$4.7B	N/A	N/A	N/A	N/A
Long-Term Investments	$268.0M-3.9%	$279.0M-8.2%	$304.0M+26.1%	$241.0M-13.0%	$277.0M-5.5%	$293.0M+215.1%	$93.0M-93.5%	$1.4B-32.1%	$2.1B+17.2%	$1.8B+1129.7%	$145.0M+57.6%	$92.0M-22.0%	$118.0M-0.8%	$119.0M	$0
Goodwill	$35.6B+2.0%	$35.0B+8.2%	$32.3B+0.4%	$32.2B-0.7%	$32.4B-2.2%	$33.1B+112.3%	$15.6B-0.4%	$15.7B-0.8%	$15.8B+2.4%	$15.4B+17.1%	$13.2B+124.6%	$5.9B-6.6%	$6.3B+2.4%	$6.1B+0.5%	$6.1B
Total Liabilities	$137.2B+4.1%	$131.8B+6.0%	$124.4B+2.3%	$121.6B-7.3%	$131.1B-4.6%	$137.5B+41.3%	$97.3B+43.5%	$67.8B+3.2%	$65.7B+6.9%	$61.5B+25.2%	$49.1B+90.5%	$25.8B+4.3%	$24.7B-9.7%	$27.4B	N/A
Current Liabilities	$43.3B+11.7%	$38.7B+2.4%	$37.8B+28.1%	$29.5B-16.1%	$35.2B+22.8%	$28.7B+83.9%	$15.6B-9.6%	$17.2B+3.6%	$16.6B+70.1%	$9.8B-10.2%	$10.9B-4.4%	$11.4B+65.6%	$6.9B+1.5%	$6.8B	N/A
Non-Current Liabilities	$93.9B+0.9%	$93.1B+7.6%	$86.5B-6.0%	$92.0B-4.1%	$95.9B-11.9%	$108.8B+33.2%	$81.7B+61.6%	$50.6B+3.1%	$49.0B-5.1%	$51.7B+35.3%	$38.2B+165.8%	$14.4B-19.3%	$17.8B-13.4%	$20.6B	N/A
Long-Term Debt	$58.9B-2.3%	$60.3B+15.6%	$52.2B-11.7%	$59.1B-7.9%	$64.2B-17.2%	$77.6B+23.2%	$63.0B+79.9%	$35.0B+13.1%	$31.0B-15.1%	$36.4B+24.6%	$29.2B+177.5%	$10.5B-26.3%	$14.3B-2.3%	$14.6B	N/A
Total Equity	-$3.3B-198.3%	$3.3B-67.9%	$10.4B-40.0%	$17.3B+12.0%	$15.4B+17.8%	$13.1B+260.0%	-$8.2B+3.2%	-$8.4B-265.7%	$5.1B+9.9%	$4.6B+17.5%	$3.9B+126.5%	$1.7B-61.2%	$4.5B+1383.4%	-$350.0M	N/A
Retained Earnings	-$15.5B-96.1%	-$7.9B-690.0%	-$1.0B-120.9%	$4.8B+53.0%	$3.1B+196.4%	$1.1B-77.6%	$4.7B+40.1%	$3.4B-38.3%	$5.5B+24.7%	$4.4B+94.8%	$2.2B+320.2%	$535.0M-65.9%	$1.6B	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$135.1B-1.5%	$136.5B+0.2%	$134.0B-0.9%	$133.9B-6.6%	$137.2B-3.4%	$136.2B-8.5%	$135.2B+0.3%	$143.4B+5.3%
Current Assets	$33.7B+15.1%	$33.5B+21.2%	$29.1B+13.6%	$28.5B+2.7%	$29.3B-13.5%	$27.7B-28.8%	$25.6B-22.5%	$27.8B-16.4%
Cash & Equivalents	$6.6B+1.6%	$9.4B+81.5%	$5.2B-5.3%	$5.6B-22.4%	$6.5B-50.7%	$5.2B-71.4%	$5.5B-56.9%	$7.3B-45.4%
Short-Term Investments	$0	$0-100.0%	$28.0M-9.7%	$42.0M+50.0%	$0-100.0%	$1.0M-50.0%	$31.0M+1450.0%	$28.0M+833.3%
Inventory	$5.1B+3.4%	$5.0B+11.6%	$5.0B+18.4%	$4.9B+11.0%	$5.0B+17.6%	$4.5B+6.6%	$4.2B+2.0%	$4.5B+11.8%
Accounts Receivable	$13.8B+9.4%	$12.5B0.0%	$12.6B+15.3%	$12.8B+11.3%	$12.6B+7.8%	$12.5B+4.4%	$10.9B-2.1%	$11.5B+0.5%
Long-Term Investments	$266.0M-14.2%	$268.0M-6.6%	$268.0M-3.9%	$291.0M+9.0%	$310.0M+14.0%	$287.0M-5.9%	$279.0M-8.2%	$267.0M-2.9%
Goodwill	$35.5B-0.3%	$35.6B+0.8%	$35.6B+2.0%	$35.6B+0.9%	$35.6B+6.7%	$35.3B+5.6%	$35.0B+8.2%	$35.3B+10.0%
Total Liabilities	$141.1B+2.7%	$143.1B+6.2%	$137.2B+4.1%	$136.5B-0.6%	$137.4B+1.6%	$134.7B-4.3%	$131.8B+6.0%	$137.4B+10.7%
Current Liabilities	$41.6B+4.7%	$42.1B+15.6%	$43.3B+11.7%	$39.4B-8.5%	$39.8B-5.1%	$36.4B-12.3%	$38.7B+2.4%	$43.1B+23.8%
Non-Current Liabilities	$99.4B+1.9%	$101.0B+2.7%	$93.9B+0.9%	$97.1B+3.0%	$97.6B+4.7%	$98.3B-1.0%	$93.1B+7.6%	$94.3B+5.6%
Long-Term Debt	$62.5B-0.8%	$64.5B0.0%	$58.9B-2.3%	$63.0B+7.6%	$63.0B+8.5%	$64.5B+1.1%	$60.3B+15.6%	$58.5B+5.2%
Total Equity	-$5.9B-3143.2%	-$6.7B-568.7%	-$3.3B-198.3%	-$2.6B-143.8%	-$183.0M-102.7%	$1.4B-82.3%	$3.3B-67.9%	$6.0B-50.1%
Retained Earnings	-$17.3B-50.7%	-$17.9B-87.6%	-$15.5B-96.1%	-$14.2B-186.7%	-$11.5B-205.3%	-$9.5B-299.6%	-$7.9B-690.0%	-$5.0B-632.0%

ABBV Cash Flow Statement

ABBV quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	$19.5B	$19.0B+1.2%	$18.8B-17.7%	$22.8B-8.4%	$24.9B+9.5%	$22.8B+29.5%	$17.6B+32.0%	$13.3B-0.8%	$13.4B+34.8%	$10.0B+41.5%	$7.0B-6.6%	$7.5B+112.3%	$3.5B-43.4%	$6.3B-1.2%	$6.3B+1.6%	$6.2B
Depreciation & Amortization	N/A	$8.1B-2.9%	$8.4B-3.6%	$8.7B+2.7%	$8.5B-0.6%	$8.5B+31.7%	$6.5B+220.8%	$2.0B+14.3%	$1.8B+17.6%	$1.5B+26.2%	$1.2B+42.2%	$836.0M+6.4%	$786.0M-12.4%	$897.0M-22.0%	$1.1B-9.6%	$1.3B
Stock-Based Compensation	N/A	$955.0M+4.8%	$911.0M+22.0%	$747.0M+11.3%	$671.0M-3.0%	$692.0M-8.1%	$753.0M+75.1%	$430.0M+2.1%	$421.0M+15.3%	$365.0M+3.4%	$353.0M+25.2%	$282.0M+17.0%	$241.0M+13.7%	$212.0M+13.4%	$187.0M+14.7%	$163.0M
Capital Expenditures	$1.3B	$1.2B+24.6%	$974.0M+25.4%	$777.0M+11.8%	$695.0M-11.7%	$787.0M-1.4%	$798.0M+44.6%	$552.0M-13.5%	$638.0M+20.6%	$529.0M+10.4%	$479.0M-10.0%	$532.0M-13.1%	$612.0M+24.6%	$491.0M+47.4%	$333.0M-6.5%	$356.0M
Free Cash Flow	$18.2B	$17.8B-0.1%	$17.8B-19.2%	$22.1B-9.0%	$24.2B+10.3%	$22.0B+31.0%	$16.8B+31.5%	$12.8B-0.1%	$12.8B+35.6%	$9.4B+43.7%	$6.6B-6.3%	$7.0B+138.4%	$2.9B-49.2%	$5.8B-3.9%	$6.0B+2.1%	$5.9B
Investing Cash Flow	-$6.5B	-$6.6B+68.1%	-$20.8B-936.3%	-$2.0B-222.5%	-$623.0M+73.4%	-$2.3B+93.8%	-$37.6B-6401.5%	$596.0M+159.2%	-$1.0B-267.2%	-$274.0M	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	-$12.9B	-$12.7B-144.2%	-$5.2B+69.7%	-$17.2B+30.6%	-$24.8B-30.3%	-$19.0B-65.5%	-$11.5B-161.5%	$18.7B+230.0%	-$14.4B-161.2%	-$5.5B-40.3%	-$3.9B	N/A	N/A	N/A	N/A	N/A
Dividends Paid	$12.0B	$11.7B+5.7%	$11.0B+4.6%	$10.5B+4.9%	$10.0B+8.4%	$9.3B+20.0%	$7.7B+21.2%	$6.4B+14.1%	$5.6B+35.9%	$4.1B+10.5%	$3.7B+12.8%	$3.3B+23.8%	$2.7B+4.1%	$2.6B	N/A	N/A
Share Buybacks	$1.5B	$980.0M-42.6%	$1.7B-13.4%	$2.0B+32.6%	$1.5B+59.2%	$934.0M-4.5%	$978.0M+55.5%	$629.0M-94.8%	$12.0B+752.1%	$1.4B-76.6%	$6.0B-20.5%	$7.6B+1040.8%	$665.0M+107.8%	$320.0M	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	$3.4B-33.3%	$3.8B+134.2%	$5.2B-26.0%	$7.0B+29.0%	$5.2B+126.9%	$1.6B-59.5%	$7.0B+48.3%	$5.4B-28.1%
Depreciation & Amortization	$1.9B-9.2%	$1.9B-5.1%	$2.0B-5.5%	$2.1B0.0%	$2.1B+0.1%	$2.0B-1.7%	$2.1B+1.3%	$2.1B-4.8%
Stock-Based Compensation	$166.0M-7.3%	$444.0M+8.3%	N/A	$209.0M+15.5%	$179.0M-17.9%	$410.0M+17.8%	N/A	$181.0M+39.2%
Capital Expenditures	$322.0M+19.7%	$265.0M+12.8%	$329.0M+13.1%	$381.0M+53.0%	$269.0M+11.6%	$235.0M+21.8%	$291.0M+42.0%	$249.0M+13.7%
Free Cash Flow	$3.1B-36.2%	$3.6B+154.6%	$4.9B-27.6%	$6.6B+27.8%	$4.9B+140.6%	$1.4B-63.6%	$6.8B+48.6%	$5.2B-29.3%
Investing Cash Flow	-$1.2B-1.4%	-$574.0M+21.9%	-$1.5B+21.9%	-$3.3B+60.5%	-$1.2B-7.2%	-$735.0M+92.3%	-$1.9B-134.3%	-$8.3B-2137.4%
Financing Cash Flow	-$5.1B-86.5%	$919.0M+173.1%	-$4.2B+39.3%	-$4.6B-49.4%	-$2.7B+55.6%	-$1.3B-111.6%	-$6.9B-54.2%	-$3.1B-15.4%
Dividends Paid	$3.1B+5.5%	$3.1B+5.5%	$2.9B+5.8%	$2.9B+5.8%	$2.9B+5.8%	$2.9B+5.5%	$2.8B+4.8%	$2.8B+4.7%
Share Buybacks	$9.0M-25.0%	$1.5B+54.9%	$3.0M-99.2%	$4.0M-76.5%	$12.0M+33.3%	$961.0M-27.4%	$358.0M+11833.3%	$17.0M+325.0%

ABBV Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ABBV quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Gross Margin	70.2%+0.3pp	70.0%+7.6pp	62.4%-7.6pp	70.0%+1.0pp	69.0%+2.5pp	66.4%-11.2pp	77.6%+1.2pp	76.4%+1.4pp	75.0%-2.2pp	77.3%-3.1pp	80.3%+2.5pp	77.8%+2.2pp	75.6%+0.1pp	75.5%+2.1pp	73.4%
Operating Margin	24.6%+8.4pp	16.2%-7.3pp	23.5%-7.7pp	31.2%-0.7pp	31.9%+7.1pp	24.8%-14.2pp	39.0%+19.5pp	19.5%-14.3pp	33.8%-2.6pp	36.4%+3.5pp	33.0%+15.9pp	17.1%-13.1pp	30.1%-1.5pp	31.6%+10.9pp	20.8%
Net Margin	6.9%-0.7pp	7.6%-1.4pp	8.9%-11.4pp	20.4%-0.2pp	20.5%+10.5pp	10.1%-13.6pp	23.7%+6.3pp	17.4%-1.5pp	18.8%-4.4pp	23.2%+0.7pp	22.5%+13.6pp	8.9%-13.1pp	22.0%-6.7pp	28.7%+9.0pp	19.7%
Return on Equity	N/A	128.7%+81.7pp	46.9%-21.7pp	68.6%-6.3pp	74.9%+39.6pp	35.3%	N/A	N/A	104.2%-24.2pp	128.4%-2.0pp	130.4%+28.6pp	101.8%+9.9pp	91.9%	N/A	N/A
Return on Assets	3.1%0.0pp	3.2%-0.4pp	3.6%-4.9pp	8.5%+0.7pp	7.9%+4.8pp	3.1%-5.8pp	8.8%-0.7pp	9.6%+2.1pp	7.5%-1.5pp	9.0%-0.7pp	9.7%+3.3pp	6.5%-7.7pp	14.1%-5.4pp	19.5%	N/A
Current Ratio	0.670.0x	0.66-0.2x	0.87-0.1x	0.96+0.2x	0.790.0x	0.84-2.3x	3.18+2.2x	0.98-0.3x	1.28-0.4x	1.65+0.2x	1.50+0.1x	1.41-1.2x	2.59+0.3x	2.27	N/A
Debt-to-Equity	N/A	18.15+13.1x	5.04+1.6x	3.43-0.7x	4.17-1.8x	5.93	N/A	N/A	6.07-1.8x	7.86+0.4x	7.41+1.4x	6.05+2.9x	3.18	N/A	N/A
Asset Turnover	0.460.0x	0.420.0x	0.400.0x	0.420.0x	0.38+0.1x	0.30-0.1x	0.37-0.2x	0.55+0.2x	0.400.0x	0.390.0x	0.43-0.3x	0.73+0.1x	0.640.0x	0.68	N/A
FCF Margin	29.1%-2.5pp	31.6%-9.0pp	40.6%-1.2pp	41.8%+2.6pp	39.1%+2.5pp	36.7%-1.7pp	38.4%-0.7pp	39.1%+5.6pp	33.4%+7.8pp	25.6%-5.0pp	30.6%+15.9pp	14.7%-16.0pp	30.7%-2.0pp	32.7%-1.1pp	33.8%

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Gross Margin	74.7%+2.9pp	71.9%+1.9pp	72.6%+1.7pp	66.4%-4.5pp	71.8%+0.9pp	70.0%+3.3pp	70.9%+10.8pp	70.9%+17.4pp
Operating Margin	37.9%+6.1pp	26.6%-1.4pp	N/A	12.1%-14.4pp	31.7%+4.1pp	28.0%+5.2pp	N/A	26.5%+10.1pp
Net Margin	21.3%+15.2pp	4.6%-5.0pp	10.9%+11.1pp	1.2%-9.6pp	6.1%-3.4pp	9.6%-1.5pp	-0.1%-5.9pp	10.8%-2.0pp
Return on Equity	N/A	N/A	N/A	N/A	N/A	90.6%+73.5pp	-0.7%-8.6pp	25.9%+11.2pp
Return on Assets	2.7%+2.0pp	0.5%-0.4pp	1.4%+1.4pp	0.1%-0.9pp	0.7%-0.3pp	0.9%0.0pp	0.0%-0.6pp	1.1%-0.2pp
Current Ratio	0.81+0.1x	0.800.0x	0.670.0x	0.72+0.1x	0.74-0.1x	0.76-0.2x	0.66-0.2x	0.65-0.3x
Debt-to-Equity	N/A	N/A	N/A	N/A	N/A	45.44+37.5x	18.15+13.1x	9.70+5.1x
Asset Turnover	0.130.0x	0.110.0x	0.120.0x	0.120.0x	0.110.0x	0.100.0x	0.110.0x	0.100.0x
FCF Margin	18.3%-13.3pp	23.8%+13.3pp	29.4%-15.3pp	42.1%+6.2pp	31.7%+17.6pp	10.5%-20.8pp	44.7%+12.9pp	35.9%-16.9pp

Note: Shareholder equity is negative (-$3.3B), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.67), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
AbbVie Inc. ABBV	FY2025	$61.2B	$4.2B	6.9%	$464.4B	58/100
Johnson & Johnson JNJ	FY2025	$94.2B	$26.8B	28.5%	$617.0B	37/100
AstraZeneca PLC AZN	FY2025	$58.7B	$10.2B	17.4%	$243.3B	43/100
Novartis AG NVS	FY2025	N/A	$14.0B	N/A	$268.0B	—
Eli Lilly and Company LLY	FY2025	$65.2B	$20.6B	31.7%	$1.0T	29/100

Where AbbVie Inc. Ranks

Frequently Asked Questions

What is AbbVie Inc.'s annual revenue?

AbbVie Inc. (ABBV) reported $61.2B in total revenue for fiscal year 2025. This represents a 8.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is AbbVie Inc.'s revenue growing?

AbbVie Inc. (ABBV) revenue grew by 8.6% year-over-year, from $56.3B to $61.2B in fiscal year 2025.

Is AbbVie Inc. profitable?

Yes, AbbVie Inc. (ABBV) reported a net income of $4.2B in fiscal year 2025, with a net profit margin of 6.9%.

What is AbbVie Inc.'s EBITDA?

AbbVie Inc. (ABBV) had EBITDA of $23.2B in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does AbbVie Inc. have?

As of fiscal year 2025, AbbVie Inc. (ABBV) had $5.2B in cash and equivalents against $58.9B in long-term debt.

What is AbbVie Inc.'s gross margin?

AbbVie Inc. (ABBV) had a gross margin of 70.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is AbbVie Inc.'s operating margin?

AbbVie Inc. (ABBV) had an operating margin of 24.6% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is AbbVie Inc.'s net profit margin?

AbbVie Inc. (ABBV) had a net profit margin of 6.9% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

Does AbbVie Inc. pay dividends?

Yes, AbbVie Inc. (ABBV) paid $6.65 per share in dividends during fiscal year 2025.

What is AbbVie Inc.'s free cash flow?

AbbVie Inc. (ABBV) generated $17.8B in free cash flow during fiscal year 2025. This represents a -0.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is AbbVie Inc.'s operating cash flow?

AbbVie Inc. (ABBV) generated $19.0B in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are AbbVie Inc.'s total assets?

AbbVie Inc. (ABBV) had $134.0B in total assets as of fiscal year 2025, including both current and long-term assets.

What are AbbVie Inc.'s capital expenditures?

AbbVie Inc. (ABBV) invested $1.2B in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does AbbVie Inc. spend on research and development?

AbbVie Inc. (ABBV) invested $9.1B in research and development during fiscal year 2025.

Does AbbVie Inc. buy back shares?

Yes, AbbVie Inc. (ABBV) spent $980.0M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

How many shares does AbbVie Inc. have outstanding?

AbbVie Inc. (ABBV) had 1.77B shares outstanding as of fiscal year 2025.

What is AbbVie Inc.'s current ratio?

AbbVie Inc. (ABBV) had a current ratio of 0.67 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is AbbVie Inc.'s return on assets (ROA)?

AbbVie Inc. (ABBV) had a return on assets of 3.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is AbbVie Inc.'s P/E ratio?

AbbVie Inc. (ABBV) trades at 73.6x earnings, its market capitalization divided by net income of $6.3B net income, trailing 12 months to June 30, 2026. The market capitalization is $464.4B as of Oct 5, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is AbbVie Inc.'s price-to-sales ratio?

AbbVie Inc. (ABBV) trades at 7.2x sales, its market capitalization divided by revenue of $64.4B revenue, trailing 12 months to June 30, 2026. The market capitalization is $464.4B as of Oct 5, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Why is AbbVie Inc.'s debt-to-equity ratio negative or not reported?

AbbVie Inc. (ABBV) has negative shareholder equity of -$3.3B as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is AbbVie Inc.'s Altman Z-Score?

AbbVie Inc. (ABBV) has an Altman Z-Score of 2.57, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is AbbVie Inc.'s Piotroski F-Score?

AbbVie Inc. (ABBV) has a Piotroski F-Score of 7 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are AbbVie Inc.'s earnings high quality?

AbbVie Inc. (ABBV) has an earnings quality ratio of 4.50x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can AbbVie Inc. cover its interest payments?

AbbVie Inc. (ABBV) has an interest coverage ratio of 5.21x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is AbbVie Inc.?

AbbVie Inc. (ABBV) scores 58 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.